Ascentage Pharma (6855) Corporate presentation summary

Corporate overview and financials

• Commercial-stage hematology-oncology company with dual listings on Nasdaq and HKEX, raising ~$420M pro forma cash as of 1H 2025.

• Portfolio includes 478 issued patents, 510+ pending applications, and 100+ publications.

• Global team of ~800 employees and 13 completed or ongoing global registrational trials, including 4 FDA-cleared Phase III trials.

• Headquarters in China, U.S., and Australia; incorporated in the Cayman Islands.

Commercial products and pipeline

• Two novel commercial products: Olverembatinib (BCR-ABL inhibitor) and Lisaftoclax (Bcl-2 selective inhibitor), both approved in China for specific hematologic malignancies.

• Robust late-stage pipeline includes compounds targeting BCR-ABL, Bcl-2, FAK/ALK/ROS1, MDM2-p53, PRC2, and BTK, with multiple global Phase III trials ongoing.

• Olverembatinib approved for CML-CP in China, included in NRDL, and in global Phase III trials for CML and Ph+ ALL.

• Lisaftoclax approved for CLL/SLL in China, with global Phase III trials in CLL/SLL, AML, and MDS.

Olverembatinib clinical highlights

• Demonstrates strong efficacy and safety in heavily pretreated CML-CP patients, including those with T315I mutations and prior Ponatinib/Asciminib failures.

• POLARIS-1 Phase III trial in Ph+ ALL shows 64% MRD-negative CR rate, surpassing Ponatinib's benchmark.

• Long-term follow-up confirms durable responses and favorable tolerability compared to best available therapy.

• Enhances outcomes in blast crisis CML and improves post-transplant survival.